{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T20:45:25Z","timestamp":1778964325996,"version":"3.51.4"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2018,10,8]],"date-time":"2018-10-08T00:00:00Z","timestamp":1538956800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,11,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Many African countries have introduced pneumococcal conjugate vaccine (PCV) into their routine immunization program to reduce the burden of morbidity and death that results from Streptococcus pneumoniae infection, yet immunogenicity and reactogenicity data from the region are limited for the 2 available PCV products.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We conducted a randomized trial of 13-valent PCV (PCV13) in Bobo-Dioulasso, Burkina Faso. Infants received 3 doses of PCV at 6, 10, and 14 weeks of age or at 6 weeks, 14 weeks, and 9 months of age; toddlers received 2 doses 2 months apart or 1 dose beginning at 12 to 15 months of age; and children received 1 dose between 2 and 4 years of age. We measured each participant\u2019s serotype-specific serum immunoglobulin G concentration and opsonophagocytic activity before and after vaccination. For each age group, we compared immune responses between study arms and between the standard schedule in our study and the PCV13-licensing trials.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>In total, 280 infants, 302 toddlers, and 81 children were assigned randomly and underwent vaccination; 268, 235, and 77 of them completed follow-up, respectively. PCV13 resulted in low reactogenicity in all the study arms. The vaccine elicited a strong primary immune response in infants after 2 or more doses and in children aged 1 to 4 years after 1 dose. Infants who received a booster dose exhibited a robust memory response. Immunogenicity was higher than or comparable to that observed in the PCV13-licensing trials for a majority of serotypes in all 3 age groups.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>PCV13 has a satisfactory immunogenicity and reactogenicity profile in this population. Our findings will help support decision making by countries regarding their infant and catch-up vaccination schedules.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jpids\/piy075","type":"journal-article","created":{"date-parts":[[2018,9,26]],"date-time":"2018-09-26T15:23:20Z","timestamp":1537975400000},"page":"422-432","source":"Crossref","is-referenced-by-count":4,"title":["Immunogenicity and Reactogenicity of 13-Valent Pneumococcal Conjugate Vaccine Among Infants, Toddlers, and Children in Western Burkina Faso: Results From a Clinical Trial of Alternative Immunization Schedules"],"prefix":"10.1093","volume":"8","author":[{"given":"Jennifer C","family":"Mo\u00efsi","sequence":"first","affiliation":[{"name":"Agence de M\u00e9decine Pr\u00e9ventive, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seydou","family":"Yaro","sequence":"additional","affiliation":[{"name":"Centre Muraz, Bobo-Dioulasso, Burkina Faso"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sita S","family":"Kroman","sequence":"additional","affiliation":[{"name":"Agence de M\u00e9decine Pr\u00e9ventive, Abidjan, C\u00f4te d\u2019Ivoire"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clarisse","family":"Gouem","sequence":"additional","affiliation":[{"name":"Centre Muraz, Bobo-Dioulasso, Burkina Faso"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dramane","family":"Bayane","sequence":"additional","affiliation":[{"name":"Ministry of Health, Ouagadougou, Burkina Faso"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seydou","family":"Ganama","sequence":"additional","affiliation":[{"name":"Ministry of Health, Ouagadougou, Burkina Faso"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bertrand","family":"Meda","sequence":"additional","affiliation":[{"name":"Agence de Medecine Preventive, Bobo-Dioulasso, Burkina Faso"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Boubacar","family":"Nacro","sequence":"additional","affiliation":[{"name":"Centre Hospitalier Sanou Sourou, Bobo-Dioulasso, Burkina Faso"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Berthe-Marie","family":"Njanpop-Lafourcade","sequence":"additional","affiliation":[{"name":"Agence de M\u00e9decine Pr\u00e9ventive, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soumeya","family":"Ouangraoua","sequence":"additional","affiliation":[{"name":"Centre Muraz, Bobo-Dioulasso, Burkina Faso"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Issaka","family":"Ouedraogo","sequence":"additional","affiliation":[{"name":"Agence de Medecine Preventive, Bobo-Dioulasso, Burkina Faso"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Souleymane","family":"Sakande","sequence":"additional","affiliation":[{"name":"Agence de Medecine Preventive, Bobo-Dioulasso, Burkina Faso"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francois","family":"Sawadogo","sequence":"additional","affiliation":[{"name":"Agence de Medecine Preventive, Bobo-Dioulasso, Burkina Faso"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylvie","family":"Zida","sequence":"additional","affiliation":[{"name":"Centre Muraz, Bobo-Dioulasso, Burkina Faso"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Bosco","family":"Ouedraogo","sequence":"additional","affiliation":[{"name":"Centre Muraz, Bobo-Dioulasso, Burkina Faso"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bradford D","family":"Gessner","sequence":"additional","affiliation":[{"name":"Agence de M\u00e9decine Pr\u00e9ventive, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2018,10,8]]},"reference":[{"key":"2019110600561147600_CIT0001","first-page":"1","article-title":"Cerebrospinal meningitis in Africa","volume":"28","author":"Lapeyssonnie","year":"1963","journal-title":"Bull World Health Organ"},{"key":"2019110600561147600_CIT0002","first-page":"499","article-title":"Epidemiology of bacterial meningitis in Niamey, Niger, 1981\u201396","volume":"77","author":"Campagne","year":"1999","journal-title":"Bull World Health Organ"},{"key":"2019110600561147600_CIT0003","first-page":"575","article-title":"An epidemiological study of purulent meningitis cases admitted to hospital in Dakar, 1970\u20131979","volume":"59","author":"Cadoz","year":"1981","journal-title":"Bull World Health Organ"},{"key":"2019110600561147600_CIT0004","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1086\/426436","article-title":"Bacterial meningitis in Burkina Faso: surveillance using field-based polymerase chain reaction testing","volume":"40","author":"Parent du Chatelet","year":"2005","journal-title":"Clin Infect Dis"},{"key":"2019110600561147600_CIT0005","article-title":"Pneumococcal meningitis in Burkina Faso and Togo is common, seasonal, affects all age groups, and is highly lethal","volume":"47","author":"Gessner","year":"2008","journal-title":"Clin Infect Dis"},{"key":"2019110600561147600_CIT0006","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1086\/431151","article-title":"An outbreak of serotype 1 Streptococcus pneumoniae meningitis in northern Ghana with features that are characteristic of Neisseria meningitidis meningitis epidemics","volume":"192","author":"Leimkugel","year":"2005","journal-title":"J Infect Dis"},{"key":"2019110600561147600_CIT0007","doi-asserted-by":"crossref","first-page":"e52464","DOI":"10.1371\/journal.pone.0052464","article-title":"Pneumococci in the African meningitis belt: meningitis incidence and carriage prevalence in children and adults","volume":"7","author":"Mueller","year":"2012","journal-title":"PLoS One"},{"key":"2019110600561147600_CIT0008","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1097\/01.inf.0000130951.85974.79","article-title":"Invasive pneumococcal infections among hospitalized children in Bamako, Mali","volume":"23","author":"Campbell","year":"2004","journal-title":"Pediatr Infect Dis J"},{"key":"2019110600561147600_CIT0009","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/S0140-6736(09)61204-6","article-title":"Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates","volume":"374","author":"O\u2019Brien","year":"2009","journal-title":"Lancet"},{"key":"2019110600561147600_CIT0010","doi-asserted-by":"crossref","first-page":"e0170412","DOI":"10.1371\/journal.pone.0170412","article-title":"Burden of pneumococcal disease in northern Togo before the introduction of pneumococcal conjugate vaccine","volume":"12","author":"Mo\u00efsi","year":"2017","journal-title":"PLoS One"},{"key":"2019110600561147600_CIT0011","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/00006454-200003000-00003","article-title":"Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group","volume":"19","author":"Black","year":"2000","journal-title":"Pediatr Infect J"},{"key":"2019110600561147600_CIT0012","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0140-6736(03)14022-6","article-title":"Efficacy and safety of seven-valent conjugate pneumococcal vaccine in American Indian children: group randomised trial","volume":"362","author":"O\u2019Brien","year":"2003","journal-title":"Lancet"},{"key":"2019110600561147600_CIT0013","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1056\/NEJMoa035060","article-title":"A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection","volume":"349","author":"Klugman","year":"2003","journal-title":"N Engl J Med"},{"key":"2019110600561147600_CIT0014","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1016\/S0140-6736(05)71876-6","article-title":"Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial","volume":"365","author":"Cutts","year":"2005","journal-title":"Lancet"},{"key":"2019110600561147600_CIT0015","doi-asserted-by":"crossref","first-page":"S119","DOI":"10.1097\/INF.0000000000000079","article-title":"Systematic review of the effect of pneumococcal conjugate vaccine dosing schedules on immunogenicity","volume":"33","author":"Deloria Knoll","year":"2014","journal-title":"Pediatr Infect Dis J"},{"key":"2019110600561147600_CIT0016","doi-asserted-by":"crossref","first-page":"S109","DOI":"10.1097\/INF.0000000000000078","article-title":"Systematic review of the effect of pneumococcal conjugate vaccine dosing schedules on vaccine-type invasive pneumococcal disease among young children","volume":"33","author":"Conklin","year":"2014","journal-title":"Pediatr Infect Dis J"},{"key":"2019110600561147600_CIT0017","doi-asserted-by":"crossref","first-page":"S140","DOI":"10.1097\/INF.0000000000000082","article-title":"Systematic review of the effect of pneumococcal conjugate vaccine dosing schedules on prevention of pneumonia","volume":"33","author":"Loo","year":"2014","journal-title":"Pediatr Infect Dis J"},{"key":"2019110600561147600_CIT0018","doi-asserted-by":"crossref","first-page":"S152","DOI":"10.1097\/INF.0000000000000083","article-title":"Systematic review of the effect of pneumococcal conjugate vaccine dosing schedules on vaccine-type nasopharyngeal carriage","volume":"33","author":"Fleming-Dutra","year":"2014","journal-title":"Pediatr Infect Dis J"},{"key":"2019110600561147600_CIT0019","first-page":"517","article-title":"Meeting of the strategic advisory group of experts on immunization, October 2009\u2014conclusions and recommendations","volume":"84","author":"World Health Organization","year":"2009","journal-title":"Wkly Epidemiol Rec"},{"key":"2019110600561147600_CIT0020","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1128\/CVI.00370-10","article-title":"Multilaboratory comparison of Streptococcus pneumoniae opsonophagocytic killing assays and their level of agreement for the determination of functional antibody activity in human reference sera","volume":"18","author":"Rose","year":"2011","journal-title":"Clin Vaccine Immunol"},{"key":"2019110600561147600_CIT0021","doi-asserted-by":"crossref","first-page":"3265","DOI":"10.1016\/S0264-410X(03)00230-5","article-title":"Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants","volume":"21","author":"Jodar","year":"2003","journal-title":"Vaccine"},{"key":"2019110600561147600_CIT0022","doi-asserted-by":"crossref","first-page":"e493","DOI":"10.1542\/peds.2009-3027","article-title":"Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in infants and toddlers","volume":"126","author":"Yeh","year":"2010","journal-title":"Pediatrics"},{"key":"2019110600561147600_CIT0023","doi-asserted-by":"crossref","first-page":"4192","DOI":"10.1016\/j.vaccine.2010.04.008","article-title":"Safety, tolerability, and immunologic noninferiority of a 13-valent pneumococcal conjugate vaccine compared to a 7-valent pneumococcal conjugate vaccine given with routine pediatric vaccinations in Germany","volume":"28","author":"Kieninger","year":"2010","journal-title":"Vaccine"},{"key":"2019110600561147600_CIT0024","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1016\/j.vaccine.2015.02.005","article-title":"Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine administered to older infants and children na\u00efve to pneumococcal vaccination","volume":"33","author":"Wysocki","year":"2015","journal-title":"Vaccine"},{"key":"2019110600561147600_CIT0025","first-page":"353","article-title":"Standardized interpretation of paediatric chest radiographs for the diagnosis of pneumonia in epidemiological studies","volume":"83","author":"Cherian","year":"2005","journal-title":"Bull World Health Organ"},{"key":"2019110600561147600_CIT0026","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1471-2334-10-22","article-title":"African meningitis belt pneumococcal disease epidemiology indicates a need for an effective serotype 1 containing vaccine, including for older children and adults","volume":"10","author":"Gessner","year":"2010","journal-title":"BMC Infect Dis"},{"key":"2019110600561147600_CIT0027","doi-asserted-by":"crossref","first-page":"e0149104","DOI":"10.1371\/journal.pone.0149104","article-title":"HIV infection and the epidemiology of invasive pneumococcal disease (IPD) in South African adults and older children prior to the introduction of a pneumococcal conjugate vaccine (PCV)","volume":"11","author":"Meiring","year":"2016","journal-title":"PLoS One"},{"key":"2019110600561147600_CIT0028","doi-asserted-by":"crossref","first-page":"C21","DOI":"10.1016\/j.vaccine.2012.05.055","article-title":"Introduction of pneumococcal conjugate vaccine into the public immunization program in South Africa: translating research into policy","volume":"30","author":"Madhi","year":"2012","journal-title":"Vaccine"},{"key":"2019110600561147600_CIT0029","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1056\/NEJMoa1401914","article-title":"Effects of vaccination on invasive pneumococcal disease in South Africa","volume":"371","author":"von Gottberg","year":"2014","journal-title":"N Engl J Med"},{"key":"2019110600561147600_CIT0030","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S1473-3099(14)70822-9","article-title":"Serotype-specific effectiveness and correlates of protection for the 13-valent pneumococcal conjugate vaccine: a postlicensure indirect cohort study","volume":"14","author":"Andrews","year":"2014","journal-title":"Lancet Infect Dis"}],"container-title":["Journal of the Pediatric Infectious Diseases Society"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jpids\/article-pdf\/8\/5\/422\/30437026\/piy075.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jpids\/article-pdf\/8\/5\/422\/30437026\/piy075.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,6]],"date-time":"2019-11-06T00:56:54Z","timestamp":1573001814000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jpids\/article\/8\/5\/422\/5123713"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,8]]},"references-count":30,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2018,10,8]]},"published-print":{"date-parts":[[2019,11,6]]}},"URL":"https:\/\/doi.org\/10.1093\/jpids\/piy075","relation":{},"ISSN":["2048-7193","2048-7207"],"issn-type":[{"value":"2048-7193","type":"print"},{"value":"2048-7207","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,11]]},"published":{"date-parts":[[2018,10,8]]}}}